Phenotypic Precision Medicine VL

PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris

Details
Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...

Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu

Details
Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...

Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor

Details
Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...

The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor

Details
Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...

A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher...

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer, an article published in European Urology. Drs. Wallis and Klaassen detail the analysis, objective,...

177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman

Details
The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has mostly involved androgen receptor-targeted therapies (ARTTs) and cytotoxic chemotherapy for over a decade. Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metas...

Targeted Radionuclide Therapy of Prostate Cancer - Wolfgang Weber

Details
Phil Koo, MD is joined by Wolfgang Weber, MD sharing his thoughts on the current state of PSMA based therapies. Dr. Weber discusses which patients respond well to this treatment, as well as the research being done to better understand why some patients do not respond well to this treatment. Dr. Weber concludes with a glimpse of things to come for PSMA based therapies. Biographies: Wolfgang Weber,...

TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis

Details
Ian Davis, MBBS, PhD, FRACP, and Michael Hofman, MBBS, FRACP, discuss the TheraP trial with Alicia Morgans, MD, MPH, which was presented at the ASCO 2020 virtual meeting. This study showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC), LuPSMA was more active than cabazitaxel. Drs. Hofman and Davis provide insights into how Lutetium-PSMA works mechanisti...

Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni

Details
Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...
email news signup